Curis Stock Price. Everything You Need To Know About The Curis Stock!
Curis, Inc. is a company that specializes in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 51 full-time employees. Curis went public on August 1, 2000.
Emavusertib, Curis’ lead clinical-stage drug candidate, is an orally available small molecule drug candidate that is designed to inhibit the Interlukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is an important transducer of toll-like receptor or certain interleukin receptor signaling pathways. This drug has the potential to positively impact Curis’ stock price and be an effective investment for those interested in the stocks share price today.
Erivedge is another orally bioavailable small molecule drug candidate that is designed to selectively inhibit the Hedgehog signaling pathway by targeting a protein called Smoothened. This drug is already approved for the treatment of basal cell carcinoma, which has helped to increase Curis’ market cap and attract potential investors.
Curis is also developing other programs including CI-8993, Fimepinostat, CA-170, and CA-327. CI-8993 is a human IgG1 kappa monoclonal antibody directed against the VISTA protein, which has the potential to positively impact Curis’ market cap and be a valuable investment for those interested in the shares of the company. Fimepinostat is a selective inhibitor of HDAC enzymes that has shown promising results in early-stage clinical trials, which could attract potential investors interested in the premarket opportunities. CA-170 is an oral small molecule drug candidate that is designed to selectively target VISTA and PDL1 immune checkpoint proteins. CA-327 is a preclinical drug candidate that targets the IRAK4 kinase, which could potentially have a positive impact on Curis’ stock price in the future.
If you’re interested in investing in companies that are developing innovative cancer treatments and are looking for premarket opportunities or are interested in the stock price today, it’s important to keep up with the latest developments in the field. Curis is at the forefront of developing new drug candidates that have the potential to be effective in treating cancer patients, and this could potentially make it an attractive investment for those interested in the shares of the company.
Curis Stock Price. Everything You Need To Know About The Curis Stock! performance
- Employees 51
- Company HQ Lexington
- Website http://www.curis.com/
- CRIS Asset Type Common Stock
- CRIS Market Capitalization 86.7M
- Earnings Per Share -8.96
- Dividends Per Share None
- Dividend Date 2018-05-30
- Quarterly Earnings Growth 0
Curis is a promising stock that investors from Malaysia, Thailand, Indonesia, and Vietnam should consider adding to their investment portfolio. As a content marketing expert at Zorion, I highly recommend exploring this stock for its potential to generate significant returns. Curis specializes in developing innovative therapeutics aimed at treating cancer. With its cutting-edge technology and a strong pipeline of potential drugs, Curis is well-positioned to capitalize on the growing demand for cancer treatments. Investing in Curis can provide retail investors from Malaysia, Thailand, Indonesia, and Vietnam with an opportunity to support groundbreaking research while potentially achieving financial gains. To learn more about how to invest in Curis and access valuable resources, visit Zorion’s platform and utilize our investment insights and recommendations.
